Prilenia is a biotech company focused on developing new treatments for neurodegenerative disorders. Prilenia’s lead asset, pridopidine, is in late-stage clinical development for the treatment of Huntington’s Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

Pridopidine is an oral drug candidate acting as a highly selective and potent Sigma-1 Receptor (S1R) agonist. The S1R is highly expressed in the brain where it regulates several cellular mechanisms which are important for neuronal health and are impaired in HD. Activation of the S1R by pridopidine enhances these mechanisms and improves neuronal functions and survival.

Pridopidine is currently being assessed for the treatment of HD in PROOF-HD, a global phase 3 clinical trial. The primary endpoint is the effect of pridopidine on Total Functional Capacity (TFC). The TFC scale is widely used and is an acceptable tool to capture changes in HD patients' capacity to continue working, perform household activities, eat, dress, walk, and complete simple tasks.
Extensive safety data from ~1000 HD patients demonstrate that 45 mg BID, the dose evaluated in PROOF-HD, is safe and well-tolerated with a placebo-like adverse effect profile.

Prilenia is a science driven company, dedicated to bringing hope to patients and their families suffering from neurodegenerative disease and neurodevelopmental disorders.